Equity Overview
Price & Market Data
Price: $70.08
Daily Change: -$4.05 / 5.77%
Range: $69.63 - $70.91
Market Cap: $5,261,830,144
Volume: 1,525
Performance Metrics
1 Week: 3.36%
1 Month: 13.14%
3 Months: 1.17%
6 Months: -31.61%
1 Year: -22.09%
YTD: -26.94%
Company Details
Employees: 335
Sector: Health technology
Industry: Pharmaceuticals: major
Country: Denmark
Details
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. Zealand Pharma A/S was incorporated in 1997 and is based in Søborg, Denmark.